ClinicalTrials.Veeva
Menu

Find clinical trials for Pancreatic Cancer in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Colorectal Cancer
Non-Small-Cell Lung Carcinoma
Stomach Cancer
Cancer
Ovarian Cancer
Neoplasm Metastasis
Breast Cancer

Pancreatic Cancer trials near Toronto, ON, CAN:

Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic...

Active, not recruiting
Gastric Cancer
Pancreatic Cancer
Biological: CT041

Phase 1, Phase 2

CARsgen Therapeutics

Toronto, Ontario, Canada and 15 other locations

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic...

Enrolling
Pancreatic Ductal Adenocarcinoma (PDAC)
G12D Mutated KRAS
Drug: VS-7375
Drug: cetuximab

Phase 2

Verastem

Toronto, Ontario, Canada and 28 other locations

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety...

Active, not recruiting
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Drug: Gemcitabine
Drug: Nab-paclitaxel

Phase 1

Amgen
Amgen

Toronto, Ontario, Canada and 76 other locations

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (RASolute 303)

The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combinatio...

Enrolling
Pancreatic Cancer Metastatic
Pancreatic Adenocarcinoma Metastatic
Drug: daraxonrasib
Drug: nab-paclitaxel

Phase 3

Revolution Medicines
Revolution Medicines

Toronto, Ontario, Canada and 81 other locations

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agen...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Drug: Pembrolizumab
Drug: Cetuximab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Toronto, Ontario, Canada and 7 other locations

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid ...

Enrolling
Gastroesophageal Junction Cancer
Gastric Cancer
Drug: l-leucovorin
Drug: Gemcitabine

Phase 2

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 51 other locations

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of th...

Enrolling
Esophageal Cancer
Pancreatic Adenocarcinoma
Combination Product: Pembrolizumab
Combination Product: Cisplatin

Phase 1

Pfizer
Pfizer

Toronto, Ontario, Canada and 30 other locations

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer age...

Active, not recruiting
Breast Cancer
Biliary Cancer
Drug: Camizestrant
Drug: T- Dxd

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 67 other locations

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Adv...

Enrolling
Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma
Drug: WEF-001

Phase 1, Phase 2

Auricula Biosciences Inc.

Toronto, Ontario, Canada and 3 other locations

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) ...

Enrolling
Gastric/Esophageal Cancer
Micro Satellite Stable Colorectal Cancer
Drug: Azirkitug
Drug: Telisotuzumab Adizutecan

Phase 1

AbbVie
AbbVie

Toronto, Ontario, Canada and 47 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems